Current pharmacologic treatments for pediatric anxiety disorders (eg, selective serotonin
reuptake inhibitors (SSRIs)) frequently use “one size fits all” dosing strategies based on …

In pediatric patients, the selective serotonin reuptake inhibitors (SSRIs) escitalopram and
citalopram (es/citalopram) are commonly prescribed for anxiety and depressive disorders …

Background: Selective serotonin reuptake inhibitors (SSRIs) are commonly used to treat
pediatric anxiety disorders, including generalized anxiety disorder (GAD); however, their …

Abstract Objective: Cytochrome P4502C19 (CYP2C19) is a highly polymorphic gene that
encodes an enzyme that metabolizes escitalopram and sertraline, two selective serotonin …

To the Editor: In adolescents, variability in escitalopram pharmacokinetics is linked to
CYP2C19 activity (Bousman et al., 2023; Jukic et al., 2018), and CYP2C19 metabolism …

Anxiety and depressive disorders are the most common mental health conditions affecting
children and adolescents [1, 2], and rank among the biggest drivers of healthcare burden for …

Introduction: Escitalopram is an effective and generally well-tolerated antidepressant, but
children of parents with bipolar disorder (BD) may be at increased risk for adverse events …

Objective Amygdala− ventrolateral prefrontal cortex (VLPFC) circuitry is disrupted in
pediatric anxiety disorders, yet how selective serotonin reuptake inhibitors (SSRIs) affect this …

Results ABC-CV scores improved over the course of treatment (P< 0.0001). No differences
were identified in the rate of improvement across metabolizer groups for the ABC-CV …

Pharmacogenetic testing for psychiatry is growing at a rapid pace, with multiple sites utilizing
results to help clinical decision‐making. Genotype‐guided dosing and drug selection have …